Biotin-binding receptor molecules

• US 20090011984A1
• Filed: 04/24/2007
• Published: 01/08/2009
• Est. Priority Date: 02/23/1998
• Status: Abandoned Application

• Current Assignee: Kari Airenne, Markku Kulomaa, Pauliina Lehtolainen, Seppo Yla-Herttuala, Varpu Marjomaki
• Original Assignee: Kari Airenne, Markku Kulomaa, Pauliina Lehtolainen, Seppo Yla-Herttuala, Varpu Marjomaki
• Inventors: Lehtolainen, Pauliina, Airenne, Kari, Marjomaki, Varpu, Yla-Herttuala, Seppo, Kulomaa, Markku
• Application Number:
  US11/789,739
• Publication Number:
  US 20090011984A1
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: A61K 47/557 the modifying agent being biotin
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 49/1863 the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
• CPC Class Codes: A61K 51/0478 complexes from non-cyclic ligands, e.g. EDTA, MAG3
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07K 14/465 from birds
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C12N 2799/021 for the expression of a heterologous nucleic acid

Abstract

The subject invention pertains to a transmembrane protein capable of binding to biotinylated molecules, the protein comprising a cytoplasmic domain, a membrane-spanning domain and an extracellular domain, wherein the extracellular domain comprises biotin-binding activity, and methods of use. The protein can be expressed in a cell, thereby targeting a biotinylated drug.

Claims

1. A method for enhancing action of a drug on a cell when administered to the cell, wherein the drug is modified by biotinylation and wherein the cell is transduced to express a fusion protein comprising a membrane-spanning domain of an endocytotic receptor and an extracellular domain that comprises biotin-binding activity.

2. The method according to claim 1, wherein the fusion protein further comprises a cytoplasmic domain.

3. The method according to claim 1, wherein the extracellular domain comprises a biotin-binding domain of avidin or streptavidin.

4. The method according to claim 1, wherein the receptor is scavenger receptor class A.

5. The method according to claim 1, wherein the fusion protein comprises SEQ ID NO:

2.

6. A method for treating a disease in a patient, said method comprising administering to said patient a biotinylated molecule useful in the treatment of said disease, wherein said biotinylated molecule is targeted to a target site comprising a fusion protein comprising a membrane-spanning domain of an endocytotic receptor and an extracellular domain that comprises biotin-binding activity, and wherein said biotinylated molecule exerts its effect on said target site.

7. The method according to claim 6, wherein the fusion protein further comprises a cytoplasmic domain.

8. The method according to claim 6, wherein the extracellular domain comprises a biotin-binding domain of avidin or streptavidin.

9. The method according to claim 6, wherein the receptor is scavenger receptor class A.

10. The method according to claim 6, wherein the fusion protein comprises SEQ ID NO:

2.